相关实验视频

Updated: Jul 6, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

关于EGFR-TKIs在非小细胞肺癌中的心脏毒性研究进展

Yinan Yu¹, Jianguo Zhao¹, Jiaona Xu²

¹Department of Oncology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.

Current treatment options in oncology

|December 28, 2023

概括

第三代针对非小细胞肺癌 (NSCLC) 的向疗法有希望,但可能导致心脏毒性. 早期识别和预防策略对于管理NSCLC患者心血管并发症至关重要.

科学领域:

在瘤学瘤学.
心脏病学心脏病学
药理学药理学是指药理学的学科.

背景情况:

向治疗,特别是非小细胞肺癌 (NSCLC) 的向治疗,已经在分子生物学技术方面取得了重大进展.
皮表皮生长因子受体 (EGFR) 抑制剂是关键的向疗法,三代药物具有明显的临床益处.
新兴的临床前数据突出显示了与EGFR-氨酸激酶抑制剂 (EGFR-TKI) 相关的显著心血管并发症,包括心力衰竭和QT延长.

研究的目的:

审查与第三代EGFR-TKIs相关的潜在心脏毒性,用于NSCLC治疗.
阐明EGFR-TKI诱导心脏毒性背后的机制.
为在接受向治疗的NSCLC患者中早期识别,预防和管理心脏毒性提供指导.

主要方法:

对EGFR-TKI和心脏毒性进行的临床前和临床研究的文献综述.
在接受第三代EGFR-TKI治疗的NSCLC患者中报告的心血管不良事件的分析.
对EGFR-TKI介导的心脏损伤的机制性见解的综合.

主要成果:

心脏毒性是EGFR-TKIs的一个重要问题,影响NSCLC治疗疗效和患者存活率.
第三代EGFR-TKI具有独特的心脏毒性特征,需要仔细监测.
心脏毒性机制涉及各种影响心脏功能和结构的途径.

结论:

心脏毒性是NSCLC管理的关键因素,成为第二大死亡原因.
临床医生必须在识别和管理与第三代EGFR-TKI相关的心血管风险时保持警.
积极的策略对于减轻心脏毒性和优化NSCLC患者治疗结果至关重要.

关键词:

心脏毒性有关心脏的毒性.皮肤表皮生长因子受体.非小细胞肺癌是非小细胞肺癌.铁氨酸激酶抑制剂铁氨酸激酶抑制剂

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...